ABSTRACT: Background: Expenditure on medications represents significant proportion of the total hospital budget. Establishing an effective drug cost management program is a priority area for hospitals that must begin with determining the current costs and pattern of use of medications. Objectives: The aim of the present study is to determine the cost and pattern of drug utilization at the study hospital in order to identify cost reduction opportunities. Methods: A descriptive retrospective design was used to examine the cost and pattern of drug utilization for all admissions during the period from: 1 st January 2006 to 30 th June 2006 in a university hospital in Eastern Saudi Arabis. Electronic patient data as well as manual drug cost data were obtained and merged to create the analysis database. Results: The study revealed that the total drug cost at the study hospital was SR 11,823,666.9 (mean per admission = SR 2123.5 and median per admission= SR 357.3) during the study period. Antibiotics were responsible for 35.8% of the total inpatient drug costs followed by blood products which accounted for 20.6% of the total inpatient drug costs. Further investigation of both groups revealed that the combination of piperacillin and tazobactam represented 4.5% of prescribed drugs and accounted for almost half of the inpatient antibiotic costs (SR 2,064,916.8) and 17.4% of the total hospital's inpatient drug costs. Human albumin and intravenous immunoglobulin were responsible for the majority of cost of blood products. Conclusions: Piperacillin and tazobactam, human albumin, and intravenous immunoglobulin other than Rho (D) immunoglobulin are responsible for high percentage of drug expenditure at the study hospital while being prescribed to a limited number of patients. Designing a drug cost management program to target these three drugs will increase the likelihood of achieving significant cost reduction.
INTRODUCTION
The cost of providing healthcare, and medications in particular, has dramatically increased over the past few decades. It is estimated that the costs of medications to treat patients will soon equal that of the hospitalization itself. (1) The Saudi Arabia's drug market is the largest in the Gulf Cooperation Council (GCC). In 2001, the healthcare budget allocation for Saudi Arabia was US$5.84 billion; nearly 20% of it was spent on medicines alone. (2) In 2007, it was reported that drug expenditure in Saudi Arabia reached SAR8.52 billion (US$2.27 billion). Drug expenditures in Saudi Arabia is expected to rise at a faster rate than they have in the past years; with an average increase rate of 6.8% annually to reach a value of SAR11.83 billion (US$3.2 billion) by the end of 2012. (3) Factors that contributed to the growth in overall drug expenditure include price, utilization, mix, and innovation. Price Innovation occurs when expensive, new medications become available to treat conditions previously untreatable with drug therapy (i.e., innovative therapy). (4) Several strategies were implemented to manage increasing pharmaceutical expenses including better drug data management, prescriber education and collaboration to improve cost-effectiveness of treatments, implementation of practice guidelines, forecasting of future expenses, use of therapeutic interchange and providing feedback to physicians. (1, (5) (6) (7) (8) (9) Prioritization of these methods depends on determining the potential benefit of each method and estimating the relative ease or difficulty of attaining the benefit. have correspondingly higher degrees of difficulty and complexity. (10) As the first stage of establishing an effective drug cost management program begins with determining the current costs of medications, the present study aims at determining the cost and pattern of drug utilization at the study hospital in order to identify cost reduction opportunities.
MATERIAL AND METHOD
The study was conducted at a 444-bed 
Statistical analysis:
Statistical analysis was carried out using one-way analysis of variance tests were applied. (12) The cut off value for statistical significance was set as 0.05. 5.6% of the total hospital budget. (17) Another study that investigated antibiotic utilization prevalence in two medical departments in a tertiary care university hospital revealed that piperacillin and tazobactam combination to be the most expensive antibiotic in use. (13) Moreover, the present study revealed that piperacillin and tazobactam were used in at least one case of the identified high cost diagnoses;
RESULTS
with the exception of asthma and bronchopneumonia (table 6) repercussions. (14, 21) Intravenous immunoglobulins accounted for more than 20% of prescribed blood products in the present study. A study conducted at a teaching hospital in Saudi Arabia (15) , revealed that the annual cost of intravenous immunoglobulin (IVIG) was $1.75 million, and 24.4% of which was considered inappropriate use. High economic impact of inappropriate use of IVIG was reported in other studies. (15, (22) (23) The present study revealed that arthropathy had the highest median cost per patient among the identified high cost 10 diagnoses during the study period (table   6) . Out of the 14 cases coded as arthopathy (ICD 9 CM = 710), 6 cases received intravenous immunoglobulin.
Although the use of intravenous immunoglobulin for treatment of systemic lupus erythematosus was found to be beneficial in a number of studies (24, 25) , a study (26) 
CONCLUSION AND RECOMMENDATIONS
The study provided drug cost and utilization data at the study hospital. 
